Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Filter By
2017
January
Media Release
/
Jan 31, 2017
Sandoz Canada launches Sandoz® Amphetamine XR for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Read More
2016
July
Media Release
/
Jul 07, 2016
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
Read More
June
Media Release
/
Jun 28, 2016
Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada
Read More
Media Release
/
Jun 21, 2016
Sandoz Canada Launches First Non-Prescription Naloxone Approved by Health Canada for Treating Opioid Overdoses
Read More
Media Release
/
Jun 13, 2016
Sandoz Canada concludes a new collective agreement with unionized employees at its Boucherville plant
Read More
Media Release
/
Jun 09, 2016
New data demonstrates sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products
Read More
Media Release
/
Jun 07, 2016
Sandoz Canada is committed to maintain a supply of injectable medicines during work stoppage by unionized employees at its Boucherville facility
Read More
May
Media Release
/
May 31, 2016
Sandoz broadens its pharmaceutical portfolio with EURO-PHARM's North American product line
Read More
Media Release
/
May 17, 2016
Sandoz Canada launches PrSandoz® Duloxetine, a generic version of Cymbalta*, for the treatment of depression and anxiety symptoms
Read More
March
Media Release
/
Mar 31, 2016
Sandoz Canada Inc. launches PrTOBRAMYCIN INHALATION SOLUTION, a generic version of PrTOBI* indicated for pulmonary infections in cystic fibrosis patients
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
6
of 5
Page
7
of 5
Current page
8
of 5
Page
9
of 5
Page
10
of 5
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
You are here
Home
›